Structure‐forward targeting of claudins with synthetic binders
Open Access
- 6 August 2026
- journal article
- review article
- Published by Wiley in FEBS Letters
Abstract
Claudins regulate molecular transport between cells via the paracellular route at tight junctions in epithelial and endothelial tissues and are prime targets for biologic therapies. Claudin–claudin interactions through their extracellular segments facilitate form and function of tight junction barriers, making for defined targetable surfaces. However, developing biologic or small molecule binders against claudin extracellular segments is challenging because they are small, dynamic, and no structures of assemblies exist to guide efforts to rationally design binders. Here, I review claudin targeting strategies, recent advances using natural and synthetic molecules, and the impact these molecules have had on claudin or tight junction biology. I surmise that the therapeutic promise of any molecule is dependent on deeply considering how claudins assemble and what structures they take within and outside of tight junctions. This review thus focuses on structure‐forward themes, with the hope of providing a framework for researchers to apply this knowledge in the design and development of new claudin‐binding molecules with diverse properties, mechanisms, and functions.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM138368)
This publication has 133 references indexed in Scilit:
- Claudin‐1, a Biomarker of Epithelial‐Mesenchymal Transformation, Enhances Lipid Metabolism in Colorectal Cancer Cells to Promote Tumor MetastasisThe Journal of Gene Medicine, 2025
- Storming the gate: New approaches for targeting the dynamic tight junction for improved drug deliveryAdvanced Drug Delivery Reviews, 2023
- Tight junction proteins at the blood–brain barrier: far more than claudin-5Cellular and Molecular Life Sciences, 2019
- Efficacy and safety evaluation of claudin‐4‐targeted antitumor therapy using a human and mouse cross‐reactive monoclonal antibodyPharmacology Research & Perspectives, 2016
- Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancersPflügers Archiv - European Journal of Physiology, 2016
- Claudin‐4 binder C‐CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathwayPharmacology Research & Perspectives, 2015
- Directed structural modification of Clostridium perfringens enterotoxin to enhance binding to claudin-5Cellular and Molecular Life Sciences, 2014
- Claudins and Other Tight Junction ProteinsComprehensive Physiology, 2012
- Claudin‐4‐targeted therapy using Clostridium perfringens enterotoxin for prostate cancerThe Prostate, 2011
- Claudins: multifunctional players in epithelial tight junctions and their role in cancerCellular and Molecular Life Sciences, 2006